Marker Therapeutics Inc (MRKR)

[microcapbiotech]

I think a "partnership" is the way to go.
When I owned them as small companies, that is what Seattle Genetics and Ionis (formally ISIS till they changed their name for obvious reasons) did many times.
Let the big guy pay for the trials and marketing (less dilution for us and they have the network in place), and we keep 50% of the American market (or whatever), and "X" percent of the worldwide.

I had Cubist get bought by Merck - hated it, undervalued.
I had Pharmacyclics get bought by Abbvie - hated it even with high price.
Someone got bought by Pfizer, can't remember who, I think it started with a "G" - hated it, undervalued.
Celgene buying Juno was somewhat OK with me cause the price was fair, and that tells you what MRKR should be worth, Juno was bought for 9 Billion and MRKR's technology is worth MORE than Juno's, how much more, 2 times, 3 times, 18 Billion to 27 Billion, anybody going to give us that, NO.

I think of it like this:
We get bought out by a Major, what are we (Marker) now, 5% of their company, 3%?
You know what I mean, If I LOVED the other 97% of Merck so much, I'd buy them, but I don't, so I don't want to be 3% of them.
At least with partners, we are still 50% of US and our future profits (on that ONE drug).
And still 100% US on anything we don't partner with.